Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Chimeric Antigen Receptor T-cell (CAR-T) therapy represents a promising avenue for the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC)
The selection of CAR-T cell targets aims to increase specificity and reduce side effects by focusing on proteins highly expressed on the surface of HNSCC cells and rarely in normal tissues.
A phase 1/2a clinical trial in Germany is investigating the efficacy of CLDN6 CAR-T cells, utilizing RNA-LPX technology for delivery
Hu et al. 2023 Front. Immunol. 14: 1213716
A trial reported a 69% overall disease control rate after intratumoral application of CAR-T cells targeting ERBb
Parmar et al. 2022 Cancer Treatment and Research Communications 33: 10…